Phase 3 Trial of Apitegromab for SMA Type 2, 3 on Track for This Year

Phase 3 Trial of Apitegromab for SMA Type 2, 3 on Track for This Year

311840

Phase 3 Trial of Apitegromab for SMA Type 2, 3 on Track for This Year

Scholar Rock is on track to initiate a pivotal Phase 3 trial of apitegromab in non-ambulatory patients with type 2 and type 3 spinal muscular atrophy (SMA) by the end of 2021, according to a company press release. The planned randomized, double-blind, and placebo-controlled trial will focus on people with these later-onset types of SMA who are on either Spinraza (nusinersen) or Evrysdi (risdiplam), both approved disease-modifying therapies in the U.S. Apitegromab will be given as an add-on to patients’…

You must be logged in to read/download the full post.